Free Trial
NASDAQ:TSBX

Turnstone Biologics (TSBX) Stock Price, News & Analysis

Turnstone Biologics logo
$0.35 0.00 (-0.93%)
Closing price 08/1/2025 03:47 PM Eastern
Extended Trading
$0.35 +0.00 (+0.51%)
As of 08/1/2025 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Turnstone Biologics Stock (NASDAQ:TSBX)

Key Stats

Today's Range
$0.35
$0.35
50-Day Range
$0.31
$0.38
52-Week Range
$0.29
$2.47
Volume
82,535 shs
Average Volume
90,432 shs
Market Capitalization
$8.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.45
Consensus Rating
Reduce

Company Overview

Turnstone Biologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

TSBX MarketRank™: 

Turnstone Biologics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Turnstone Biologics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Turnstone Biologics has received no research coverage in the past 90 days.

  • Read more about Turnstone Biologics' stock forecast and price target.
  • Earnings Growth

    Earnings for Turnstone Biologics are expected to grow in the coming year, from ($3.32) to ($0.89) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Turnstone Biologics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Turnstone Biologics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Turnstone Biologics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Turnstone Biologics' valuation and earnings.
  • Percentage of Shares Shorted

    1.63% of the float of Turnstone Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Turnstone Biologics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Turnstone Biologics has recently increased by 648.40%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Turnstone Biologics does not currently pay a dividend.

  • Dividend Growth

    Turnstone Biologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.63% of the float of Turnstone Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Turnstone Biologics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Turnstone Biologics has recently increased by 648.40%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Turnstone Biologics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Turnstone Biologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    32.10% of the stock of Turnstone Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    52.51% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Turnstone Biologics' insider trading history.
Receive TSBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter.

TSBX Stock News Headlines

This New Rule Could Change Everything
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
Turnstone Biologics Corp. (TSBX) - Yahoo Finance
See More Headlines

TSBX Stock Analysis - Frequently Asked Questions

Turnstone Biologics' stock was trading at $0.4969 at the start of the year. Since then, TSBX stock has decreased by 29.5% and is now trading at $0.3502.

Turnstone Biologics Corp. (NASDAQ:TSBX) announced its earnings results on Thursday, May, 8th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.25.

Turnstone Biologics (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at $12.00 per share.

Turnstone Biologics' top institutional investors include Deltec Asset Management LLC (0.46%).
View institutional ownership trends
.

Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Turnstone Biologics investors own include Cara Therapeutics (CARA), JPMorgan Chase & Co. (JPM), Avino Silver & Gold Mines (ASM), Bank of America (BAC), Intel (INTC) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

Last Earnings
5/08/2025
Today
8/01/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TSBX
CIK
1764974
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

High Price Target
$0.50
Low Price Target
$0.40
Potential Upside/Downside
+28.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$70.84 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-162.79%
Return on Assets
-124.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.70
Quick Ratio
3.70

Sales & Book Value

Annual Sales
$19.31 million
Price / Sales
0.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.36 per share
Price / Book
0.26

Miscellaneous

Outstanding Shares
23,140,000
Free Float
15,713,000
Market Cap
$8.10 million
Optionable
Not Optionable
Beta
1.35

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:TSBX) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners